Robert W. Baird Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price
by Amy Steele · The Cerbat GemIntellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its target price raised by equities researchers at Robert W. Baird from $7.00 to $13.00 in a report issued on Monday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Robert W. Baird’s target price indicates a potential downside of 3.96% from the company’s previous close.
Several other equities analysts have also recently weighed in on the stock. Royal Bank Of Canada raised their target price on shares of Intellia Therapeutics from $9.00 to $15.00 and gave the company a “sector perform” rating in a research note on Tuesday, March 3rd. Leerink Partners raised their target price on shares of Intellia Therapeutics from $27.00 to $29.00 and gave the company an “outperform” rating in a research note on Tuesday, March 3rd. Citizens Jmp raised their target price on shares of Intellia Therapeutics from $21.00 to $28.00 and gave the company a “market outperform” rating in a research note on Tuesday, March 3rd. Canaccord Genuity Group decreased their target price on shares of Intellia Therapeutics from $54.00 to $48.00 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Finally, KeyCorp set a $25.00 target price on shares of Intellia Therapeutics in a research note on Wednesday, January 28th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $20.00.
View Our Latest Stock Analysis on Intellia Therapeutics
Intellia Therapeutics Stock Down 0.7%
Shares of NASDAQ:NTLA traded down $0.09 during midday trading on Monday, hitting $13.54. The stock had a trading volume of 18,633,455 shares, compared to its average volume of 4,718,198. Intellia Therapeutics has a 12 month low of $6.83 and a 12 month high of $28.25. The business’s 50-day simple moving average is $13.57 and its 200-day simple moving average is $12.97. The company has a market cap of $1.60 billion, a P/E ratio of -3.54 and a beta of 1.99.
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last released its earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.16. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The business had revenue of $23.02 million during the quarter, compared to analysts’ expectations of $12.17 million. During the same period last year, the business earned ($1.27) earnings per share. The firm’s revenue was up 78.4% on a year-over-year basis. As a group, equities analysts predict that Intellia Therapeutics will post -3.53 earnings per share for the current year.
Institutional Investors Weigh In On Intellia Therapeutics
Hedge funds have recently added to or reduced their stakes in the business. Comerica Bank lifted its holdings in Intellia Therapeutics by 45.8% during the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after purchasing an additional 901 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Intellia Therapeutics during the 2nd quarter valued at $26,000. Blue Bell Private Wealth Management LLC acquired a new stake in shares of Intellia Therapeutics during the third quarter worth $30,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Intellia Therapeutics during the third quarter worth $30,000. Finally, Advisory Services Network LLC acquired a new stake in shares of Intellia Therapeutics during the third quarter worth $33,000. Institutional investors and hedge funds own 88.77% of the company’s stock.
Key Intellia Therapeutics News
Here are the key news stories impacting Intellia Therapeutics this week:
- Positive Sentiment: Intellia reported positive Phase 3 (HAELO) results: the single‑dose CRISPR therapy met the primary and all key secondary endpoints, showed favorable safety/tolerability, and freed most patients from attacks and ongoing therapy during the six‑month evaluation — a potential first for in‑vivo gene editing. This is the core fundamental catalyst supporting upside for NTLA. Read More.
- Positive Sentiment: Intellia has initiated a rolling BLA submission to the FDA for lonvo‑z (NTLA‑2002) and said it could launch in the U.S. in H1 2027 if approved — a clear near‑term regulatory pathway that can materially de‑risk commercialization expectations. Read More.
- Positive Sentiment: Major outlets (Reuters, CNBC) covered the pivotal success, increasing visibility and institutional/retail attention — media coverage often amplifies volatility and liquidity around biotech milestones. Read More.
- Positive Sentiment: Unusual options activity: traders bought ~5,980 call options (≈92% above average call volume), signaling short‑term bullish positioning or hedging ahead of regulatory/news flow — this can increase implied volatility and intraday upside pressure.
- Positive Sentiment: Retail interest spiked in premarket coverage and commentary pushing buy narratives, which can drive short‑term momentum and retail‑led volume surges. Read More.
- Neutral Sentiment: Analyst/sector framing: Market commentary lists NTLA among gene‑editing names that could benefit from M&A activity around a patent cliff — this is a longer‑term thematic consideration rather than immediate price driver. Read More.
- Negative Sentiment: Despite the positive trial news, some coverage noted the stock fell in parts of the session — indicating profit‑taking, skepticism about valuation/timing of approval, or that expectations were already priced in. That dynamic can limit near‑term gains even after favorable trial data. Read More.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.
Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.